Bringing our innovative science to those with urgent unmet medical needs
Everything we do at Hansa Biopharma is driven by our mission in life: to develop lifesaving and life altering immunomodulating therapies, bring them to the patients with rare conditions who need them, and generate value to society at large.
Founded in 2007 in Lund, Sweden, Hansa is today a fully integrated, commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative treatments to address the serious unmet medical needs of people living with rare immunological conditions. The first therapeutic product developed from our proprietary antibody-cleaving enzyme technology platform was conditionally authorized in 2020 in the European Union (EU)/EAA and United Kingdom as desensitization treatment in highly sensitized patients waiting for a potentially lifesaving kidney transplant.
And this is only the first step. Our antibody-cleaving enzyme technology platform has potential applications across a wide spectrum of disease areas and indications. We have therefore built a broad and valuable pipeline that spans pre-kidney transplantation desensitization and post-transplantation antibody-mediated organ rejection (AMR), and rare IgG-mediated autoimmune conditions, as well as cancer. And we are also evaluating our enzyme technology in the exciting area of gene therapy.
We aim to become a global leader in the development of therapies for rare immunologic diseases and conditions, and to achieve this we need outstanding people. We are building a high-performance team by attracting and integrating the most talented and experienced candidates, while creating a rewarding, productive and stimulating workplace for our employees. Our commitment to this effort has been evidenced by the certification of Hansa as a “Great Place to Work” for three consecutive years by the Great Place to Work Institute based primarily on employee feedback. In addition, Hansa has been selected among the best workplaces in Sweden in 2023.
Hansa is on an exciting and transformative journey. I am proud of what we have achieved so far as a team and am eager to pursue the many opportunities ahead of us. What motivates everyone of us every single day is the confidence that by successfully bringing our cutting-edge science from the laboratory to the bedside of the patients, we will have a truly meaningful impact on the lives of people living with rare immunologic diseases and conditions and empower them to lead long and healthy lives.
Søren Tulstrup, President and CEO